Skip to main content

Table 2 Immunohistochemical biomarkers in primary hepatic malignant vascular tumor

From: Primary hepatic malignant vascular tumors: a follow-up study of imaging characteristics and clinicopathological features

Immunohistochemical biomarkers PHA EHE MHP IHE
Epithelial marker
 CK 7 (64%) 8 (53%) 0 2 (15%)
 Hepatocytes 6 (55%) 4 (27%) 0 0
 CK8/18 6 (55%) 6 (40%) 0 0
Vascular endothelial marker
 CD31 11 (100%) 15 (100%) 3 (100%) 13 (100%)
 CD34 11 (100%) 15 (100%) 3 (100%) 13 (100%)
 ERG 9 (82%) 13 (87%) 2 (67%) 13 (100%)
 FaVIII 9 (82%) 9 (60%) 1 (33%) 7 (54%)
 FLI-1 9 (82%) 9 (60%) 1 (33%) 7 (54%)
Mesenchymal marker
 Vimentin 4 (36%) 2 (13%) 0 0
 EMA 3 (27%) 0 0 0
 CD117 2 (18%) 0 0 0
 Dog-1 0 0 0 0
Perivascular epithelioid cell marker
 HMB45 0 0 2 (67%) 0
 Melan-A 0 0 2 (67%) 0
Cell proliferation marker
 Ki-67, median, % (range) 30 (1–60) 5 (2–20) 30 (10–30) 10 (1–20)
  1. Note: PHA Primary hepatic angiosarcoma; EHE Epithelioid hemangioendothelioma; MHP Malignant hemangiopericytoma; IHE Infantile hemangioendothelioma; CK Cytokeratin; EMA Epithelial membrane antigen; CD Cluster of differentiation; HMB45 Human melanoma black monoclonal antibody